1. Koulenti D, Xu E, Song A, et al. Emerging treatment options for infections by multidrug-resistant Gram-positive microorganisms. Microorganisms. 2020;8(2):191.
2. MicuRx Pharmaceuticals. China NMPA approves MicuRx’s contezolid for treatment of drug-resistant bacterial infection [media release]. 2 Jun 2021. http://www.micurx.com/.
3. National Medical Products Administration. The State Food and Drug Administration approves the listing of contezolid tablets. 2021. http://www.nmpa.gov.cn/yaowen/ypjgyw/20210602083301144.html?type=pc&m=. Accessed 8 Jun 2021.
4. Shanghai MicuRx Pharmaceutical Co. Ltd. Youxitai 优喜泰® (contezolid 康替唑胺 tablets): Chinese prescribing information. Shanghai: Shanghai MicuRx Pharmaceutical Co., Ltd.; 2021.
5. MicuRx Pharmaceuticals. MicuRx reports positive top-line results of a China phase 3 clinical trial for novel antibiotic contezolid in complicated skin and soft tissue infections [media release]. 20 Sep 2019. http://www.micurx.com.